The 16p13.3 (PDPK1) genomic gain in prostate cancer: A potential role in disease progression

Translational Oncology

Volumn 5, Issue 6, 2012, Pages 453-460

  Choucair, Khalil A ^a   Guérard, Karl Philippe ^a   Ejdelman, Joshua ^a   Chevalier, Simone ^a   Yoshimoto, Maisa ^b   Scarlata, Eleonora ^a   Fazli, Ladan ^c   Sircar, Kanishka ^a,e   Squire, Jeremy A ^b   Brimo, Fadi ^a   Cunha, Isabela W ^d   Aprikian, Armen ^a   Gleave, Martin ^c   Lapointe, Jacques ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d A C CAMARGO CANCER CENTER   (Brazil)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CELL MOTILITY; CHROMOSOME 16P; CHROMOSOME MAP; CONTROLLED STUDY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; PROSTATE CANCER; WESTERN BLOTTING;

EID: 84871694036     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12286     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, and Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212-236.
2. Canadian Cancer Society's Steering Committee on Cancer Statistics (2011). Canadian Cancer Statistics 2011. Canadian Cancer Society, Toronto, Ontario.
3. Yuan X and Balk SP (2009). Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27, 36-41.
4. DeMarzo AM, Nelson WG, Isaacs WB, and Epstein JI (2003). Pathological and molecular aspects of prostate cancer. Lancet 361, 955-964.
5. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, et al. (2009). Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 69, 7793-7802.
6. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, et al. (2007). Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67, 8229-8239.
7. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, et al. (2011). Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 21, 47-55.
8. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
9. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, and Squire JA (2007). FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97, 678-685.
10. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, et al. (2010). Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102, 678-684.
11. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, and Mak TW (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39.
12. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, et al. (1997). 3-Phosphoinositidedependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7, 776-789.
13. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, and Pollack JR (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67, 8504-8510.
14. Moyzis RK, Albright KL, Bartholdi MF, Cram LS, Deaven LL, Hildebrand CE, Joste NE, Longmire JL, Meyne J, and Schwarzacher-Robinson T (1987). Human chromosome-specific repetitive DNA sequences: novel markers for genetic analysis. Chromosoma 95, 375-386.
15. Pinner S and Sahai E (2008). PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10, 127-137.
16. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101, 811-816.
17. Jenkins RB, Qian J, Lieber MM, and Bostwick DG (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57, 524-531.
18. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, et al. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15, 559-565.
19. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, et al. (2009). 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 69, 6299-6306.
20. Shen H, Zhu Y, Wu YJ, Qiu HR, and Shu YQ (2008). Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet Cytogenet 181, 100-107.
21. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, et al. (2009). PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218, 505-513.
22. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, Prescott AR, Lucocq JM, and Alessi DR (2002). Essential role of PDK1 in regulating cell size and development in mice. EMBO J 21, 3728-3738.
23. Primo L, di Blasio L, Roca C, Droetto S, Piva R, Schaffhausen B, and Bussolino F (2007). Essential role of PDK1 in regulating endothelial cell migration. J Cell Biol 176, 1035-1047.
24. Liu Y, Wang J, Wu M, Wan W, Sun R, Yang D, Sun X, Ma D, Ying G, and Zhang N (2009). Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 7, 944-954.
25. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, and Papadopoulos N (2010). Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA 107, 2598-2603.
26. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, et al. (2009). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castrationresistant prostate cancer. Cancer Res 69, 2912-2918.
27. Peifer C and Alessi DR (2008). Small-molecule inhibitors of PDK1. ChemMedChem 3, 1810-1838.